Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Current Assets (2016 - 2025)

Historic Current Assets for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to $15.9 million.

  • Lipocine's Current Assets fell 2230.69% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.9 million, marking a year-over-year decrease of 2230.69%. This contributed to the annual value of $22.3 million for FY2024, which is 236.01% down from last year.
  • As of Q3 2025, Lipocine's Current Assets stood at $15.9 million, which was down 2230.69% from $18.4 million recorded in Q2 2025.
  • Lipocine's 5-year Current Assets high stood at $47.2 million for Q2 2021, and its period low was $15.9 million during Q3 2025.
  • Its 5-year average for Current Assets is $30.7 million, with a median of $27.1 million in 2023.
  • As far as peak fluctuations go, Lipocine's Current Assets surged by 11914.09% in 2021, and later tumbled by 3302.72% in 2023.
  • Over the past 5 years, Lipocine's Current Assets (Quarter) stood at $46.4 million in 2021, then fell by 26.4% to $34.1 million in 2022, then plummeted by 33.03% to $22.9 million in 2023, then dropped by 2.36% to $22.3 million in 2024, then dropped by 28.63% to $15.9 million in 2025.
  • Its Current Assets was $15.9 million in Q3 2025, compared to $18.4 million in Q2 2025 and $20.3 million in Q1 2025.